The M&A and Life Sciences teams advised Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) on its definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion.
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. Etavopivat, Forma Therapeutics’ lead development candidate, is an investigational oral, once-daily, selective pyruvate kinase-R (PKR) activator being developed to improve anemia and red blood cell health in people with SCD, a seriously debilitating, life-threatening and life shortening disease.
The Goodwin team consisted of Stuart Cable, Lisa Haddad, Andrew Goodman, Tevia Pollard, Cynthia (Xiaoyue) Li, Patrick O’Brien, Stephanie Barbanell and Adanna Uwazurike (Public M&A); William Collins, Gabriela Morales-Rivera, Kathryn Clerici and Kimberly Rodriguez (Corporate); Monica Patel, Adrean Taylor and Chris Jones (ERISA & Executive Compensation); Jennifer Fay (Employment); Janet Andolina and Matthew Tippett (Tax); Caroline Bullerjahn and Viktors Dindzans (Litigation); Arman Oruc, Charlie Stewart and Simone Waterbury (Antitrust); Roger Cohen and Heath Ingram (Healthcare); Susan Lee; Catherine McCarty (Intellectual Property); Chris Denn (Licensing); Jacqueline Klosek and Paul Thompson (Privacy); and Richard Matheny and Axel Urie (Global Trade).
For more details, read the press release.